What does “Pifeltro resistance” mean?
Pifeltro (doravirine) resistance means the virus (HIV) changes so doravirine no longer controls it as well. This can happen when doravirine is used while the virus already has resistance-associated mutations, or after treatment failure where resistance mutations develop over time.
What resistance mutations are linked to doravirine (Pifeltro)?
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Resistance to NNRTIs is typically driven by mutations in HIV reverse transcriptase that change how the NNRTI binds. The practical takeaway is that certain NNRTI resistance patterns can reduce doravirine activity, and clinicians use genotype testing to check for these mutations before and during therapy.
How does someone get doravirine resistance?
Common pathways include:
- Starting Pifeltro with HIV that already contains resistance mutations (transmitted resistance).
- Taking therapy inconsistently, which can allow the virus to replicate and accumulate resistance.
- Treatment failure that is not addressed quickly enough, letting resistant strains expand.
How is resistance detected—do you need a genotype test?
When resistance is suspected (for example, viral load is not suppressed or rebounds), clinicians typically order HIV resistance testing (genotype). The genotype result helps determine whether doravirine should be continued, changed, or replaced with an alternative regimen.
What happens if a patient has doravirine resistance?
If resistance reduces doravirine effectiveness, viral suppression may fail and the HIV virus can rebound. Continuing a failing regimen can allow additional resistance mutations to build, limiting future treatment options. In practice, clinicians switch to a new combination based on the resistance profile and prior drug exposure.
How does doravirine resistance compare with resistance to other NNRTIs?
Because doravirine is an NNRTI like drugs such as efavirenz and rilpivirine, NNRTI resistance mechanisms can overlap. Some mutations can reduce susceptibility to multiple NNRTIs, which is why genotype results matter more than assuming one NNRTI will still work after failure on another.
What treatment alternatives are used if doravirine can’t be used?
Switch regimens depend on the individual’s history and genotype, but generally involve combining drugs from other HIV classes (for example, boosted protease inhibitors and/or integrase inhibitors) that can still suppress the virus despite NNRTI resistance.
What if the resistance question is really about patents (DrugPatentWatch angle)?
If your question is about whether doravirine (Pifeltro) faces patent or exclusivity changes tied to new entrants (and not clinical resistance), DrugPatentWatch can help track patent status and related litigation. You can check doravirine coverage here: https://www.drugpatentwatch.com/ .